Table 1.
Cancer detection rates in the 10th screening round of the Göteborg randomised screening trial, by three different screening strategies.
| Attendees in the 10th screening round (n=384) |
PSA ≥3 (SB) | PSA ≥3 + MRI (TB) |
PSA ≥1.8 + MRI (TB) |
|---|---|---|---|
| No. of men with elevated PSA | 77 | 77 | 172 |
| No. of men with MRI indication (proportion) | 0 | 77/384 (20%) | 172/384 (45%) |
| No. of men undergoing MRI (proportion) | 0 | 65/77 (84%) | 127/172 (74%) |
| No. of men with positive MRI (proportion) | 0 | 21/65 (32%) | 42/127 (33%) |
| No. of men with bx indication (proportion†) | 77 (20%) | 21 (6.5%) | 42 (15%) |
| No. of men biopsied (proportion) | 70/77 (91%) | 20/21(95%) | 40/42 (95%) |
| No. of PC detected (rate††) | 18 (5.2%) | 12 (3.9%) | 19 (7.0%) |
| No. of significant PC (rate) | 14 (4.0%) | 11 (3.6%) | 16 (5.9%) |
| No. of insignificant cancer (rate) | 4 (1.2%) | 1 (0.32%) | 3 (1.1%) |
| No. of GS ≥7 PC (rate) | 9 (2.6%) | 7 (2.3%) | 10 (3.7%) |
| No. of GS 6 PC (rate) | 9 (2.6%) | 5 (1.6%) | 9 (3.3%) |
Proportions calculated with the following formula: number of men with a positive MRI, divided by number of men attending MRI, multiplied by proportion of men with elevated PSA.
Rates calculated with the following formula: number of cancers detected, divided by number of men biopsied, multiplied by proportion of men with a biopsy indication.
Cancers classified as significant or insignificant according to the modified Epstein criteria (insignificant cancer = Clinical stage T1c, Gleason score ≤6, PSA density ≤0.15 ng/ml/m3, ≤2 sectors with cancer, unilateral cancer).
PC = prostate cancer, bx = biopsy, GS = Gleason score, PSA = prostate-specific antigen, MRI = magnetic resonance imaging, TB = targeted biopsy, SB = systematic biopsy